The Telectronics Accufix — the Pacemaker Wire That Speared Six Hearts

When Telectronics Pacing Systems issued a voluntary worldwide recall of its Accufix atrial “J” pacemaker leads on November 3, 1994 — a recall the U.S. Food and Drug Administration classified as Class I, its most severe category, reserved for products with a reasonable probability of causing serious injury or death — the device had already been doing precisely that. The Accufix lead carried, just behind its J-shaped tip, a thin metal “retention wire” whose only job was to hold the curve that anchored the electrode in the right atrial appendage. That wire fractured from metal fatigue, and the broken end could protrude through the lead’s polyurethane insulation and lacerate the atrial wall, the great vessels, even the aorta. The feature engineered to keep the lead in place became the mechanism that perforated the heart.

The gap between the design intent and the delivered harm was unusually stark because the failure was not rare. Radiographic screening of recalled-population patients found definite retention-wire fracture in 22.4 percent of leads examined, with the incidence climbing toward 25.6 percent on re-evaluation; the multicenter study put the fracture risk at roughly 5.6 percent per year. Roughly 45,000 leads had been implanted worldwide — about 25,000 of them in U.S. patients — across models 330-801 and 329-701. By the time of recall, Telectronics had logged two deaths and two non-fatal injuries; the worldwide registry would eventually record 40 spontaneous injuries, including 19 pericardial tamponades and six deaths.

What made the Accufix case distinct from a simple defective-device story was the trap it set after withdrawal. The lead could not simply be swapped like a battery: it was screwed into beating cardiac tissue and scarred in by years of healing. Extraction was itself lethal — fatal complications occurred in 0.4 percent of intravascular extraction procedures, 16 deaths among 4,023 attempts. Patients and cardiologists faced a documented dilemma with death on both arms: leave a fracturing wire in the heart and accept an annual protrusion risk, or pull it and accept an extraction-mortality risk that, for many low-fracture-risk patients, exceeded the hazard of leaving it alone. Telectronics funded the Accufix Research Institute to run the registry and study that quantified that trade-off, then exited the pacing business; the U.S. litigation consolidated as MDL-1057 and resolved in a settlement establishing a $58 million medical-monitoring and claims fund.